HK65397A - Heterocylic amines having central nervous system activity - Google Patents

Heterocylic amines having central nervous system activity

Info

Publication number
HK65397A
HK65397A HK65397A HK65397A HK65397A HK 65397 A HK65397 A HK 65397A HK 65397 A HK65397 A HK 65397A HK 65397 A HK65397 A HK 65397A HK 65397 A HK65397 A HK 65397A
Authority
HK
Hong Kong
Prior art keywords
nervous system
central nervous
system activity
compounds
alkyl
Prior art date
Application number
HK65397A
Inventor
Malcolm W Moon
Richard F Heier
Jeanette K Morris
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of HK65397A publication Critical patent/HK65397A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/03—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/04—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing quinolizine ring systems directly condensed with at least one six-membered carbocyclic ring, e.g. protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing a quinolizine ring system condensed with only one six-membered carbocyclic ring, e.g. julolidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/06—Peri-condensed systems

Abstract

Tricyclic nitrogen containing compounds, having central nervous system activity of structural formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are independently hydrogen, C1-6 alkyl, alkenyl, or alkynyl, C3-10 cycloalkyl, or R1 and R2 are joined to form a C3-7 cyclic amine which can contain additional heteroatoms; X is hydrogen, C1-6 alkyl, halogen, hydroxy, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl; A is SO2, N, CH, CH2, CHCH3, C=O, C=S, C-SCH3, C=NH, C-NH2, C-NHCH3, C-NHCOOCH3, or C-NHCN; B is CH2, CH, C=O, N, NH or N-CH3; n is 0 or 1; and D is CH, CH2, C=O, O, N, NH or N-CH3. These new compounds are suitable for treating schizophrenia, Parkinson's disease, anxiety, depression or as compounds for lowering blood pressure in animal or human hosts.
HK65397A 1989-06-09 1997-05-15 Heterocylic amines having central nervous system activity HK65397A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36437489A 1989-06-09 1989-06-09
PCT/US1990/002621 WO1990015058A1 (en) 1989-06-09 1990-05-15 Heterocyclic amines having central nervous system activity

Publications (1)

Publication Number Publication Date
HK65397A true HK65397A (en) 1997-05-23

Family

ID=23434241

Family Applications (1)

Application Number Title Priority Date Filing Date
HK65397A HK65397A (en) 1989-06-09 1997-05-15 Heterocylic amines having central nervous system activity

Country Status (15)

Country Link
EP (1) EP0480939B1 (en)
JP (1) JP2955358B2 (en)
KR (1) KR0167346B1 (en)
AT (1) ATE117688T1 (en)
AU (1) AU626427B2 (en)
CA (1) CA2051697C (en)
DE (1) DE69016430T2 (en)
DK (1) DK0480939T3 (en)
ES (1) ES2067744T3 (en)
FI (2) FI96310C (en)
HK (1) HK65397A (en)
HU (2) HU210264B (en)
NO (1) NO301421B1 (en)
RU (1) RU2023712C1 (en)
WO (1) WO1990015058A1 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05117276A (en) * 1991-10-23 1993-05-14 Sumitomo Pharmaceut Co Ltd New tricyclic quinoxalinedione derivative
TW260660B (en) * 1993-04-22 1995-10-21 Sumitomo Pharma
DE4314593A1 (en) * 1993-04-28 1994-11-03 Schering Ag Pyrido (1,2,3-de) quinoxaline derivatives, process for their preparation and their use of medicines
NZ269018A (en) * 1993-07-27 1996-12-20 Upjohn Co 5-amino-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one derivatives; pharmaceutical compositions
FR2719843B1 (en) * 1994-05-10 1996-06-07 Synthelabo Derivatives of 5,6-dihydro-4h-imidazo [2 ', 1': 2,3] imidazo- [4,5,1-ij] quinoline and 4,5-dihydroimidazo [1,2-a] pyrrolo- [1,2,3-cd] benzimidazole, their preparation and their therapeutic application.
EP0705834A1 (en) * 1994-07-27 1996-04-10 Ciba-Geigy Ag Quinoxaline-2,3-diones with an azaheterocyclic fused ring
EP0705835A1 (en) * 1994-09-01 1996-04-10 Ciba-Geigy Ag Quinoxalic-2,3-diones with an oxa or thiaheterocyclic fused ring
RU2170735C2 (en) 1995-08-10 2001-07-20 Байер Аг Derivatives of halogen-substituted benzimidazole and their acid-additive salts, intermediate compounds and fungicide agent
US6288075B1 (en) 1998-02-26 2001-09-11 Rhone-Poulenc Rorer S.A. Thiazolo[5,4,3-ij]quinolines, preparation and medicines containing the same
FR2760237B1 (en) * 1997-02-28 1999-04-16 Rhone Poulenc Rorer Sa THIAZOLOBENZOHETEROCYCLES, THEIR PREPARATION AND THE MEDICINES CONTAINING THEM
US6197339B1 (en) * 1997-09-30 2001-03-06 Pharmacia & Upjohn Company Sustained release tablet formulation to treat Parkinson's disease
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
CA2358865A1 (en) * 1999-02-05 2000-08-10 Pharmacia & Upjohn Company Process to prepare (5r)-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]-quinolin-2(1h)-one
US7074927B2 (en) 1999-05-13 2006-07-11 Pharmacia & Upjohn Company Heterocyclic amines having central nervous system activity
DE19954707A1 (en) * 1999-11-13 2001-05-17 Merck Patent Gmbh Imidazole compounds as phosphodiesterase VII inhibitors
GB0008939D0 (en) 2000-04-11 2000-05-31 Glaxo Group Ltd Process for preparing substituted benzimidazole compounds
NZ531171A (en) 2000-04-21 2005-03-24 Upjohn Co Cabergoline-type compounds for treating fibromyalgia and chronic fatigue syndrome
AR033520A1 (en) * 2000-04-27 2003-12-26 Upjohn Co (5R) - (METHYLAMINE) -5,6-DIHIDRO-4H-IMIDAZO [4,5,1-IJ] QUINOLIN-2 (1H) -TIONA
AU2001283393B2 (en) * 2000-08-16 2005-09-22 Pharmacia & Upjohn Company Compounds for the treatment of addictive disorders
US6759405B2 (en) 2000-11-03 2004-07-06 Wyeth Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031202A1 (en) 2000-11-03 2003-09-10 Wyeth Corp CYCLOPENTA (B) (1,4) DIAZEPINO (6,7,1-HI) INDOLES AND DERIVATIVES
US6858604B2 (en) 2000-11-03 2005-02-22 Wyeth Cyclohepta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
FR2825705B1 (en) 2001-06-08 2005-05-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTI-BACTERIANS
FR2835186B1 (en) 2002-01-28 2006-10-20 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS ACTIVE AS BETA-LACTAMASES INHIBITORS
TW200307540A (en) 2002-04-25 2003-12-16 Wyeth Corp [1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TWI312781B (en) * 2002-04-25 2009-08-01 [1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307682A (en) * 2002-04-25 2003-12-16 Wyeth Corp 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
US20050226926A1 (en) 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AR040683A1 (en) * 2002-07-25 2005-04-13 Pharmacia Corp COMPOSITION OF SUSTAINED RELEASE TABLETS INCLUDED BY AN AGONIST OF DOPAMINE RECEIVERS
AR040680A1 (en) * 2002-07-25 2005-04-13 Pharmacia Corp COMPOSITION OF SUSTAINED RELEASE TABLETS
FR2844273B1 (en) 2002-09-05 2008-04-04 Aventis Pharma Sa NOVEL HETEROCYCLIC COMPOUNDS, METHOD AND INTERMEDIARY PREPARATION AND USE AS MEDICAMENT, IN PARTICULAR AS INHIBITORS OF BETA-LACTAMASES AND ANTI-BACTERIALS.
CA2502729A1 (en) * 2002-10-25 2004-05-06 Haiyan Wu Use of heterocyclic amine-type compounds as neuroprotective agents
WO2005011611A2 (en) * 2003-07-31 2005-02-10 Irm, Llc Bicyclic compounds and compositions as pdf inhibitors
US20050250803A1 (en) * 2003-11-26 2005-11-10 Pfizer Inc Combination of dopamine agonists and monoamine reuptake inhibitors
JP4785847B2 (en) 2004-08-13 2011-10-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Tablet formulation with extended release comprising pramipexole or a pharmaceutically acceptable salt thereof, process for its production and use thereof
BRPI0513848A (en) 2004-08-13 2008-05-20 Boehringer Ingelheim Int Pramipexole prolonged-release pellet formulation or a pharmaceutically acceptable salt thereof, method of manufacture thereof and use thereof
PE20060939A1 (en) * 2004-11-05 2006-11-10 Wyeth Corp METABOLITES DERIVED FROM [1,4] DIAZEPIN [6,7,1-IJ] QUINOLINE AND PREPARATION PROCEDURE
GT200500317A (en) 2004-11-05 2006-10-27 PROCESS TO PREPARE QUINOLINE COMPOUNDS AND PRODUCTS OBTAINED FROM THEM
PE20070078A1 (en) 2005-06-14 2007-03-08 Schering Corp MACROCICLIC HETEROCYCLIC COMPOUNDS AS ASPARTILE PROTEASE INHIBITORS
AR054849A1 (en) 2005-07-26 2007-07-18 Wyeth Corp DIAZEPINOQUINOLINAS, SYNTHESIS OF THE SAME, AND INTERMEDIARIES TO OBTAIN THEM
US20140080813A1 (en) 2012-09-14 2014-03-20 AbbVie Deutschland GmbH & Co. KG Tricyclic quinoline and quinoxaline derivatives
IN2015DN02070A (en) 2012-09-14 2015-08-14 Abbvie Deutschland

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3563389A (en) * 1988-05-09 1989-11-29 Upjohn Company, The Anxiolytic/anti-depressant 2,3-dihydro-1h-phenalen-2-amines

Also Published As

Publication number Publication date
EP0480939A1 (en) 1992-04-22
FI96310C (en) 1996-06-10
WO1990015058A1 (en) 1990-12-13
HU211702A9 (en) 1995-12-28
FI96687C (en) 1996-08-12
DK0480939T3 (en) 1995-07-10
DE69016430D1 (en) 1995-03-09
FI944704A0 (en) 1994-10-07
HU905216D0 (en) 1992-02-28
CA2051697A1 (en) 1990-12-10
NO914827L (en) 1992-02-07
DE69016430T2 (en) 1995-06-01
JPH04506071A (en) 1992-10-22
JP2955358B2 (en) 1999-10-04
CA2051697C (en) 1996-10-08
RU2023712C1 (en) 1994-11-30
NO301421B1 (en) 1997-10-27
FI96687B (en) 1996-04-30
HUT60269A (en) 1992-08-28
AU626427B2 (en) 1992-07-30
FI944704A (en) 1994-10-07
AU5743890A (en) 1991-01-07
HU210264B (en) 1995-03-28
FI915715A0 (en) 1991-12-04
ES2067744T3 (en) 1995-04-01
EP0480939B1 (en) 1995-01-25
KR0167346B1 (en) 1999-01-15
ATE117688T1 (en) 1995-02-15
NO914827D0 (en) 1991-12-06
KR920701204A (en) 1992-08-11
FI96310B (en) 1996-02-29

Similar Documents

Publication Publication Date Title
HK65397A (en) Heterocylic amines having central nervous system activity
FI102175B (en) A process for the preparation of therapeutically useful piperazine derivatives
BG104187A (en) 4-phenyl-pyridine derivatives
DE68906309D1 (en) METHOD FOR TREATING CACHEXIA AND SPECIFIC COMPOUNDS TO BE APPLIED.
ZA89389B (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
FI883402A (en) ESTERNITRATDERIVAT.
EP0428313A3 (en) Pyrimidone derivatives and analogs in the treatment of asthma or certain skin disorders
PT85008A (en) Process for the preparation of 2-thiazolil-imidazo ]1,2-c" pyrimidines of their salts of acid addition and of pharmaceutical composicoes containing them
YU46706B (en) PROCEDURE FOR OBTAINING AMIDE COMPOUNDS
KR910004559A (en) 4- (N-substituted amino) -2-butynyl-1-urea and thiourea and derivatives thereof, muscarinic agents acting on the central nervous system
KR920701122A (en) New Bicyclic Amino-Substituted Compounds
EG17859A (en) Process for preparing of spiro-imidazolines as aldose reductase inhibitors
KR840007726A (en) Method for preparing mitomycin analogs
DE60005525D1 (en) 2-AMINOTETRALINE FOR TREATING GLAUCOMA
IE830685L (en) Piperidine derivatives.
KR910700236A (en) Substituted 3-azabicyclo [3,1,1] heptane, preparation method thereof and use thereof
DE69327077T2 (en) Carbamoylpyrrolidone derivatives for the treatment of depression and cerebrovascular disorders
EP0420464A3 (en) 3-isoxazolone derivatives, their preparation and their therapeutic uses
PT85429A (en) Process for the preparation of pharmaceutical compositions

Legal Events

Date Code Title Description
PF Patent in force